极光激酶B
极光激酶
极光抑制剂
有丝分裂
激酶
癌症研究
主轴检查点
药物靶点
丝氨酸
癌症
生物
主轴装置
细胞生物学
遗传学
细胞分裂
细胞周期
磷酸化
细胞
作者
Antal H. Kovacs,Dong Zhao,Jinqiang Hou
出处
期刊:Molecules
[MDPI AG]
日期:2023-04-11
卷期号:28 (8): 3385-3385
被引量:11
标识
DOI:10.3390/molecules28083385
摘要
The Aurora kinases (A, B, and C) are a family of three isoform serine/threonine kinases that regulate mitosis and meiosis. The Chromosomal Passenger Complex (CPC), which contains Aurora B as an enzymatic component, plays a critical role in cell division. Aurora B in the CPC ensures faithful chromosome segregation and promotes the correct biorientation of chromosomes on the mitotic spindle. Aurora B overexpression has been observed in several human cancers and has been associated with a poor prognosis for cancer patients. Targeting Aurora B with inhibitors is a promising therapeutic strategy for cancer treatment. In the past decade, Aurora B inhibitors have been extensively pursued in both academia and industry. This paper presents a comprehensive review of the preclinical and clinical candidates of Aurora B inhibitors as potential anticancer drugs. The recent advances in the field of Aurora B inhibitor development will be highlighted, and the binding interactions between Aurora B and inhibitors based on crystal structures will be presented and discussed to provide insights for the future design of more selective Aurora B inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI